| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/18/2004 | DE10242763A1 New polynucleotide encoding mutant human glucose transporter, useful for identifying antidiabetic agents that can be used to treat diabetes types I or II |
| 03/18/2004 | DE10242318A1 Orthopoxvirusantigene und deren Verwendung Orthopoxvirusantigene and their use |
| 03/18/2004 | DE10240866A1 New polypeptide that binds immunoglobulin E and alters cytokine synthesis, useful for treating e.g. atopic eczema, asthma or allergy, also its encoding nucleic acid |
| 03/18/2004 | DE10239832A1 New sarcolysine derivatives, e.g. amide or peptide compounds, useful as anticancer agents with reduced toxicity to healthy cells |
| 03/18/2004 | DE10130985B4 Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente A method for the diagnosis of sepsis and severe infections by determining soluble cytokeratin-1 fragments |
| 03/18/2004 | CA2536010A1 Boronic acid salts useful in parenteral formulations for selective thrombin inhibition |
| 03/18/2004 | CA2535792A1 Boronic acid salts ant their use in the treatment of thrombosis |
| 03/18/2004 | CA2535788A1 Multivalent metal salts of boronic acids for treating thrombosis |
| 03/18/2004 | CA2498353A1 Antifreeze proteins isolated from forage grasses and methods for their use |
| 03/18/2004 | CA2498319A1 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| 03/18/2004 | CA2498296A1 Zinc transporter compositions for the treatment of cardiovascular diseases |
| 03/18/2004 | CA2497960A1 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| 03/18/2004 | CA2497836A1 A method of modulating endothelial cell activity |
| 03/18/2004 | CA2497833A1 A method of modulating cellular activity and molecules for use therein |
| 03/18/2004 | CA2497794A1 Modified glp-1 receptor agonists and their pharmacological methods of use |
| 03/18/2004 | CA2497777A1 Modified asialo-interferons and uses thereof |
| 03/18/2004 | CA2497772A1 Asialo-interferons and the treatment of liver cancer |
| 03/18/2004 | CA2497750A1 Orthopoxvirus vectors, genes and products thereof |
| 03/18/2004 | CA2497719A1 Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof |
| 03/18/2004 | CA2497696A1 Increasing the absorption of substances via the skin and mucous membranes |
| 03/18/2004 | CA2497660A1 Allergy vaccines |
| 03/18/2004 | CA2497634A1 Compositions comprising bone marrow cells, demineralized bone matrix and various site-reactive polymers for use in the induction of bone and cartilage formation |
| 03/18/2004 | CA2497552A1 Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| 03/18/2004 | CA2497497A1 Regulators for implantation |
| 03/18/2004 | CA2497350A1 Decoy-oligonucleotide-inhbition of cd40-expression |
| 03/18/2004 | CA2497254A1 Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same |
| 03/18/2004 | CA2497193A1 Methods and compositions for tissue regeneration |
| 03/18/2004 | CA2496891A1 Novel actin-related cytoskeletal protein lacs |
| 03/18/2004 | CA2496888A1 Epitope sequences |
| 03/18/2004 | CA2496566A1 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
| 03/18/2004 | CA2495480A1 Interferon and immunoglobulin fc fragment hybrid |
| 03/18/2004 | CA2495043A1 Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
| 03/17/2004 | EP1398632A1 P2y11 receptor agonists and the use in the field of erythropoiesis |
| 03/17/2004 | EP1398380A1 Orthopoxvirus antigens and use thereof |
| 03/17/2004 | EP1398379A2 Compounds for immunotherapy and diagnosis of tuberculosis |
| 03/17/2004 | EP1398377A1 Growth differentation Factor-7 |
| 03/17/2004 | EP1398372A1 Lipid phosphate phosphatases and uses thereof for treating neuronal diseases |
| 03/17/2004 | EP1398328A1 Hydroxyalkyl starch derivatives |
| 03/17/2004 | EP1398327A1 Method of producing hydroxyalkyl starch derivatives |
| 03/17/2004 | EP1398326A2 Monoclonal antibodies against recombinant stratum corneum chymotryptic enzyme (SCCE) |
| 03/17/2004 | EP1398324A1 Use of recombinant gelatin-like proteins as plasma expanders and compositions suitable for plasma substitution |
| 03/17/2004 | EP1398323A1 Murine androgen receptor complex-associated protein |
| 03/17/2004 | EP1398322A1 HASylated polypeptides, especially HASylated erythropoietin |
| 03/17/2004 | EP1398039A1 Morphogenic proteins for enhancing cognitive function |
| 03/17/2004 | EP1398038A1 Botulinum toxin pharmaceutical compositions |
| 03/17/2004 | EP1398037A2 Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery |
| 03/17/2004 | EP1398031A1 Use of 6-amino-quinoline-5,8-quinones and nucleic acids associated with senescence for the treatment of tumors |
| 03/17/2004 | EP1398030A2 Dipeptidyl peptidase IV effectors |
| 03/17/2004 | EP1398025A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein |
| 03/17/2004 | EP1398024A2 Uses for thyroid hormone compounds |
| 03/17/2004 | EP1398019A1 Method for protecting and modulating the dermal-epidermal junction |
| 03/17/2004 | EP1397516A1 Antisense modulation of interleukin 12 p40 subunit expression |
| 03/17/2004 | EP1397507A1 Methods and compositions for treating cardiovascular disease using 10218 |
| 03/17/2004 | EP1397500A2 Improved transfection of eukaryotic cells with linear polynucleotides by electroporation |
| 03/17/2004 | EP1397495A2 22437, a human sulfatase and uses therefor |
| 03/17/2004 | EP1397494A2 Fungal gene cluster associated with pathogenesis |
| 03/17/2004 | EP1397492A2 Modified and stabilized gdf propeptides and uses thereof |
| 03/17/2004 | EP1397489A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 03/17/2004 | EP1397486A2 Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8 and their use in diagnostic and therapeutic applications |
| 03/17/2004 | EP1397484A2 Methods and products related to fgf dimerization |
| 03/17/2004 | EP1397386A2 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same |
| 03/17/2004 | EP1397383A2 Secreted polypeptide and their use in the treatment of bone disorders |
| 03/17/2004 | EP1397380A2 Multiple antigenic peptide displaying multiple copies of an epitope of a plaque-forming polypeptide and methods of using same |
| 03/17/2004 | EP1397163A2 Method for the diagnosis and therapy of renal cell carcinoma |
| 03/17/2004 | EP1397160A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers |
| 03/17/2004 | EP1397158A2 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS |
| 03/17/2004 | EP1397157A2 Antibacterial agent |
| 03/17/2004 | EP1397156A2 Oral administration of parathyroid hormone and calcitonin |
| 03/17/2004 | EP1397155A1 Sustained release formulation |
| 03/17/2004 | EP1397154A2 Abin-mediated hepatitis protection |
| 03/17/2004 | EP1397153A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 03/17/2004 | EP1397152A1 Use of tripeptide gpe for treating or preventing symptoms of parkinson's disease |
| 03/17/2004 | EP1397151A2 Wnv core protein/capsid interacting protein and uses of the same |
| 03/17/2004 | EP1397150A2 Somatostatin agonists |
| 03/17/2004 | EP1397139A1 Pharmaceutical combinations |
| 03/17/2004 | EP1397124A2 Use of antidiabetics for making a medicine with cicatrizing effect |
| 03/17/2004 | EP1397106A1 Dental restorative materials |
| 03/17/2004 | EP1307218A4 Obesity controlling method |
| 03/17/2004 | EP1292316A4 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use |
| 03/17/2004 | EP1259112A4 Nutritional intervention composition for enhancing and extending satiety |
| 03/17/2004 | EP1240201A4 Oxidized apolipoproteins and methods of use |
| 03/17/2004 | EP1214397B1 Method for the selective protection of proliferating normal cells and the selective eradication of tumor cells having an inactive p53 pathway |
| 03/17/2004 | EP1176871A4 Novel beta-secretase and modulation of beta-secretase activity |
| 03/17/2004 | EP1144365B1 Inhibitors of alpha-4 beta-1 mediated cell adhesion |
| 03/17/2004 | EP1079851A4 Use of anti-prolactin agents to treat proliferative conditions |
| 03/17/2004 | EP0998488B1 Polyol-amino acid compounds having anti-helicobacter pylori activity |
| 03/17/2004 | EP0996633B1 Anti-inflammatory peptides derived from c-reactive protein |
| 03/17/2004 | EP0975775B1 Regulatory system for inducible expression of genes with lambdoid promoters |
| 03/17/2004 | EP0970107B1 Cyclosporine derivatives and uses thereof |
| 03/17/2004 | EP0951471B1 Cycloalkyl inhibitors of protein farnesyltransferase |
| 03/17/2004 | EP0948523B1 Peptidomimetic inhibitors of the human cytomegalovirus protease |
| 03/17/2004 | EP0946590B1 Dihydroxypropyl cysteine peptide and agent containing this peptide |
| 03/17/2004 | EP0915974B1 Modified tie-2-receptor ligands |
| 03/17/2004 | EP0825885B1 Pulmonary delivery of aerosolized medicaments |
| 03/17/2004 | EP0762881B1 Use of active agents for the manufacture of medicaments for the treatment of rheumatoid arthritis |
| 03/17/2004 | EP0731807B1 N-2 substituted purines |
| 03/17/2004 | EP0573611B1 Improved epitode displaying phage |
| 03/17/2004 | CN1483041A GLP-1 fusion protein |
| 03/17/2004 | CN1483040A Heart ankyrin repeat protein gene upstream sequence, carrier containing the same sequence and usage thereof |
| 03/17/2004 | CN1482919A Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings |